BiopharmaTrend.com

A2A Pharmaceuticals

A2A Pharmaceuticals

Private company
A2A PHARMACEUTICALS

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections. Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development.


Founded
2016
Status
Private company
Geography
United States of America based
Funding
$3 M

Products

SCULPT

The SCULPT™ process builds and evaluates small molecule libraries, consisting of thousands to millions of members. Iterations are performed until …

Read more

Services

No services posted yet


This data is part of our proprietary analytics report:

This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality

Go to home page